HC Wainwright Reiterates “Neutral” Rating for Sage Therapeutics (NASDAQ:SAGE)
HC Wainwright reaffirmed their neutral rating on shares of Sage Therapeutics (NASDAQ:SAGE – Free Report) in a research report sent to investors on Tuesday,Benzinga reports. They currently have a $12.00 price target on the biopharmaceutical company’s stock. A number of other brokerages have also weighed in on SAGE. Bank of America began coverage on Sage […]
HC Wainwright reaffirmed their neutral rating on shares of Sage Therapeutics (NASDAQ:SAGE – Free Report) in a research report sent to investors on Tuesday,Benzinga reports. They currently have a $12.00 price target on the biopharmaceutical company’s stock. A number of other brokerages have also weighed in on SAGE. Bank of America began coverage on Sage […]
